Monte Rosa Therapeutics (GLUE) Interest & Investment Income (2020 - 2026)

Monte Rosa Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 62.58% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $15.1 million (up 30.54% YoY), while the FY2025 annual figure was $12.9 million, up 22.49% from the prior year.
• Interest & Investment Income was $5.6 million for Q1 2026 at Monte Rosa Therapeutics, up from $3.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $5.6 million in Q1 2026 to a low of $149000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.5 million across 5 years, with a median of $2.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income surged 15207.69% in 2022, then declined 5.05% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $2.0 million in 2022, then climbed by 18.99% to $2.4 million in 2023, then grew by 9.59% to $2.6 million in 2024, then jumped by 42.16% to $3.7 million in 2025, then jumped by 51.56% to $5.6 million in 2026.
• The last three Interest & Investment Income figures came in at $5.6 million (Q1 2026), $3.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.